Uses of oxygenated cholesterol sulfates (OCS)

US11612609B2 · kind B2 · utility

Assignees

• Durect Corporation · US
• Virginia Commonwealth University · US

Inventors

• Shunlin Ren · Richmond, US
• Felix Theeuwes · Los Altos, US
• James E. Brown · Los Gatos, US
• WeiQi Lin · Emerald Hills, US

Key dates

• Filing date: Aug 3, 2020
• Grant date: Mar 28, 2023
• Expiry date: Aug 13, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P13/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).